Cancer vaccine that teaches the body to seek and destroy tumours sends three lymphoma patients into remission
- The treatment injects an immune system stimulant directly into the tumour
- It was tested on 11 people with lymphoma cancer in a clinical trial
- But researchers say it has potential for many types of cancer including breast
A cancer vaccine that teaches the body to fight tumours has put three lymphoma patients into remission.
The vaccine is injected directly into the tumour and teaches the immune system to destroy it, as well as seek other cancerous cells.
Researchers tested it on 11 patients with lymphoma and said some were in full remission for months and even years.
Trials have been so successful that experts believe it offers hope for many other cancers, including those of the breast, head and neck.
Researchers at New York’s Mount Sinai Hospital tested the treatment – which is injected directly into the tumour to stimulate the immune system – on 11 patients
Although the treatment is called a vaccine, it doesn’t prevent cancer. Instead, it teaches the person’s immune system to fight disease.
Researchers at New York’s Mount Sinai Hospital injected tumours with a stimulant that recruits immune cells called dendritic cells.
After treating the tumour with a low dose of radiotherapy, a second stimulant was injected which activated the dendritic cells.
This then instructed T cells to kill cancerous cells throughout the body, while sparing non-cancerous cells, according to the study published in Nature Medicine.
This led to three of the patients to be put into remission as the treatment shrunk both the initial tumour targeted and other ones throughout the body.
People with lymphoma have abnormal lymphocytes – white blood cells that help fight infection – that have divided out of control.
The lymphocytes can collect in any part of the body, most often in the armpits, neck or groin.
Lead author Dr Joshua Brody, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, said: ‘The in situ vaccine approach has broad implications for multiple types of cancer.’
In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy.
According to the researchers, the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves.
They are ‘extremely optimistic’ about how effective this may be in further trials, and even described the tumour after treatment as a ‘cancer vaccine factory’.
Dr Eric Jacobsen, clinical director of the Dana-Farber Cancer Institute’s lymphoma program, told CNBC the results are exciting but said more research is needed as this was a small study.
Dr Jacobsen, who was not involved in the study, said: ‘It’s definitely proof of concept, but larger studies are definitely needed and additional strategies to try to get more than three out of 11 patients to respond.’
However, the results warranted another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer.
It is also being tested in the lab in liver and ovarian cancer.
Experts praised the findings of the study.
Dr Silvia Formenti, chairwoman of radiation oncology at Weill Cornell Medicine and NewYork-Presbyterian, who was not involved, said ‘it’s really promising’.
She told CNBC: ‘And the fact you get not only responses in treated areas, but areas outside the field [of treatment with radiation] is really significant.’
Lymphoma cancer is a cancer of the lymphatic system which is part of the immune system. There are two main types – Hodgkin lymphoma and Non-Hodgkin lymphoma.
Every year around 1,700 people are diagnosed with Hodgkin lymphoma in the UK and 8,110 in the US.
And 13,500 British people with Non Hodgkin lymphoma and about 74,200 Americans.
WHAT IS LYMPHOMA?
Lymphoma is a cancer of the lymph nodes, which is the body’s disease-fighting network.
That network consists of the spleen, bone marrow, lymph nodes and thymus gland.
There are various types of lymphoma, but two main ones: non-Hodgkin’s and Hodgkin’s.
Both have much better prognoses than many types of cancer.
WHAT IS HODGKIN’S LYMPHOMA?
Hodgkin’s lymphoma is a type of cancer that starts in the white blood cells. It is named after Thomas Hodgkin, an English doctor who first identified the disease in 1832.
It affects around 1,950 people each year in the UK, and 8,500 a year in the US.
Hodgkin’s lymphoma is most common between the ages of 20 and 24, and 75 and 79.
Five-year survival rates:
The survival rates are much more favorable than most other cancers.
- Stage 1: 90%
- Stage 2: 90%
- Stage 3: 80%
- Stage 4: 65%
- a painless swelling in the armpits, neck and groin
- heavy night sweating
- extreme weight loss
- shortness of breath
- lowered immunity
- a family history of the condition
- those who are overweight
- stem cell or bone marrow transplants
WHAT IS NON-HODKIN’S LYMPHOMA?
Non-Hodgkin lymphoma can occur anywhere in the body but is usually first noticed in the lymph nodes around sufferers’ necks.
Non-Hodgkin’s lymphoma affects around 13,700 new people every year in the UK. In the US, more than 74,600 people are diagnosed annually.
It is more common in males than females, and it is commonly diagnosed either in a patient’s early 20s or after the age of 55.
Five-year survival rates:
Survival can vary widely with NHL.
The general survival rate for five years is 70 percent, and the chance of living 10 years is approximately 60 percent.
- Painless swellings in the neck, armpit or groin
- Heavy night sweating
- Unexplained weight loss of more than one-tenth of a person’s body
- over 75
- have a weak immune system
- suffer from celiac disease
- have a family history of the condition
- have had other types of cancer
It depends on the number and locations of the body affected by Non-Hodgkin lymphoma.
Therapy typically includes chemotherapy.